The combination of accelerating revenue growth, improved profitability, strong clinical data supporting HEPZATO, and an optimistic 2026 outlook suggests continued momentum. Traders should monitor procedure volume trends and the pace of new center activations as leading indicators of future revenue.
DCTH drugs
DCTH drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $9.00entry
- T+1 · 9mo ago −1.11%α −0.66% · $8.90
- T+5 · 9mo ago +0.89%α +2.02% · $9.08
- T+20 · 8mo ago +1.44%α +7.85% · $9.13
- T+60 · 6mo ago +27.22%α +19.47% · $11.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Delcath Systems reported strong financial results for Q4 and full year 2025, with full-year revenue up 129% year-over-year to $85.2 million and full-year net income of $2.7 million. The company also issued 2026 guidance calling for at least $100 million in revenue, representing over 17% growth, driven by continued HEPZATO adoption and clinical momentum from positive trial data.
Key Financial Metrics
Key Facts
- Full year 2025 revenue was $85.2 million, up 129% from $37.2 million in 2024
- HEPZATO KIT revenue grew to $78.8 million in 2025 from $15.1 million in 2024
- Full year 2025 net income was $2.7 million vs. a net loss of $26.4 million in 2024
- Non-GAAP adjusted EBITDA was $25.1 million in 2025 vs. a loss of $2.5 million in 2024
- Company guided to at least $100 million in total revenue for 2026, implying >17% growth
Financial Impact
Revenue grew 129% YoY to $85.2M in 2025 with a dramatic swing from a $26.4M net loss in 2024 to $2.7M net income in 2025, and guidance points to continued strong growth with >$100M revenue expected in 2026
Segment Breakdown
| Segment | Revenue |
|---|---|
| HEPZATO KIT | $78.8M |
| CHEMOSAT | $6.4M |
Risk Factors
- R&D and SG&A expenses increased significantly in 2025, which could pressure margins if revenue growth slows
- The stock may already reflect positive expectations, making it vulnerable to any miss on the $100M+ 2026 revenue guidance
- Reliance on continued HEPZATO adoption and reimbursement stability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-012004 |
| Document: dcth-20260226.htm | 0001628280-26-012004 |
| Document: 0001628280-26-012004-index-headers.html | 0001628280-26-012004 |
| Document: 0001628280-26-012004-index.html | 0001628280-26-012004 |
| Document: 0001628280-26-012004.txt | 0001628280-26-012004 |
Track record
12 reports on DCTH
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $21.38 Now $19.87 −7.06% settles Feb 10
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $20.27 Now $19.87 −1.97% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $14.82 Now $19.87 +34.08% settles Feb 2
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $14.86 Now $19.87 +33.71% settles Jan 26
- Oct 19, 202628d ago SC 13D/A Neutral 4/10 Entry $14.37 Now $19.87 +38.27% settles Jan 14
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $11.77 to $16.48 Now $19.87 +68.89% ▲ +40.08% +35.68% vs SPY
- May 14, 202626w ago 8-K Neutral 3/10 Entry $11.46 to $16.67 Now $19.87 +73.39% ▲ +45.46% +41.87% vs SPY
- May 7, 202627w ago 8-K Neutral 5/10 Entry $11.24 to $13.04 Now $19.87 +76.78% ▲ +16.01% +12.18% vs SPY
- Apr 2, 202632w ago DEFA14A Neutral 3/10 Entry $9.63 to $12.59 Now $19.87 +106.33% ▲ +30.74% +16.58% vs SPY
- Mar 2, 202637w ago Insider Cluster Bullish 6/10 Entry $8.93 to $10.83 Now $19.87 +122.51% ▲ +21.28% +11.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers